A ‘first in human’ clinical trial examining the small molecule drug ONC201 in cancer patients with advanced solid tumors shows that this investigational drug is well tolerated at the recommended phase II dose. That’s according to Rutgers Cancer...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2mUCAf7
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
by Demin Li, Carol Bentley, Jenna Yates, Maryam Salimi, Jenny Greig, Sarah Wiblin, Tasneem Hassanali, Alison H. Banham Therapeutic monoclon...
-
Web version of a book about Subversion. Work in progress, however already very complete. The book should be published by O'Reilly and As...
-
by Kerstin Jost, Isabelle Pramana, Edgar Delgado-Eckert, Nitin Kumar, Alexandre N. Datta, Urs Frey, Sven M. Schulzke Background Poor contro...
-
Summary We tested whether prophylactic droperidol and ondansetron, in combination with a moderate dose of dexamethasone, were equally effe...
-
by Rita Rey-Baños, Luis E. Sáenz de Miera, Pedro García, Marcelino Pérez de la Vega Retrotransposons with long terminal repeats (LTR-RTs) a...
-
Through the Wormhole: Is There an Edge to... Science - 43 min - ★ It is commonly theorized that the universe began with the Big Bang... Thro...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nL9dMr via IFTTT
-
http://ift.tt/2p7HgAl
-
by Sarah K. Sharman, Bianca N. Islam, Yali Hou, Margaux Usry, Allison Bridges, Nagendra Singh, Subbaramiah Sridhar, Satish Rao, Darren D. Br...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου